SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Masafumi Matsuo, Yasuhiro Takeshima, Hisahide Nishio, Contributions of Japanese patients to development of antisense therapy for DMD, Brain and Development, 2016, 38, 1, 4

    CrossRef

  2. 2
    Bastian Salewsky, Gabriele Hildebrand, Susanne Rothe, Ann Christin Parplys, Janina Radszewski, Moritz Kieslich, Petra Wessendorf, Harald Krenzlin, Kerstin Borgmann, André Nussenzweig, Karl Sperling, Martin Digweed, Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application, Molecular Therapy, 2016, 24, 1, 117

    CrossRef

  3. 3
    Mariana Loperfido, Susan Jarmin, Sumitava Dastidar, Mario Di Matteo, Ilaria Perini, Marc Moore, Nisha Nair, Ermira Samara-Kuko, Takis Athanasopoulos, Francesco Saverio Tedesco, George Dickson, Maurilio Sampaolesi, Thierry VandenDriessche, Marinee K. Chuah, piggyBactransposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts, Nucleic Acids Research, 2016, 44, 2, 744

    CrossRef

  4. 4
    Jeffrey Chung, Andrea L. Smith, Sarah C. Hughes, Gabriela Niizawa, Hoda Z. Abdel-Hamid, Edwin W. Naylor, Timothy Hughes, Paula R. Clemens, Twenty-year follow-up of newborn screening for patients with muscular dystrophy, Muscle & Nerve, 2016, 53, 3
  5. 5
    Volker Straub, Marta Bertoli, Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies?, Neuromuscular Disorders, 2016, 26, 2, 111

    CrossRef

  6. 6
    Sabrina Paganoni, Anne-Marie Thomas, Walter R. Frontera, Pathology and Intervention in Musculoskeletal Rehabilitation, 2016,

    CrossRef

  7. 7
    Xihua Li, Lei Zhao, Shuizhen Zhou, Chaoping Hu, Yiyun Shi, Wei Shi, Hui Li, Fang Liu, Bingbing Wu, Yi Wang, A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China, Orphanet Journal of Rare Diseases, 2015, 10, 1, 5

    CrossRef

  8. 8
    Jerry R Mendell, Zarife Sahenk, Vinod Malik, Ana M Gomez, Kevin M Flanigan, Linda P Lowes, Lindsay N Alfano, Katherine Berry, Eric Meadows, Sarah Lewis, Lyndsey Braun, Kim Shontz, Maria Rouhana, Kelly Reed Clark, Xiomara Q Rosales, Samiah Al-Zaidy, Alessandra Govoni, Louise R Rodino-Klapac, Mark J Hogan, Brian K Kaspar, A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy, Molecular Therapy, 2015, 23, 1, 192

    CrossRef

  9. 9
    A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD), Human Gene Therapy Clinical Development, 2015, 26, 2, 92

    CrossRef

  10. You have free access to this content10
    Simon Guiraud, Huijia Chen, David T. Burns, Kay E. Davies, Advances in genetic therapeutic strategies for Duchenne muscular dystrophy, Experimental Physiology, 2015, 100, 12
  11. 11
    J Scharner, N Figeac, J A Ellis, P S Zammit, Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies, Gene Therapy, 2015, 22, 6, 503

    CrossRef

  12. 12
    Graham McClorey, Matthew J Wood, An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies, Current Opinion in Pharmacology, 2015, 24, 52

    CrossRef

  13. 13
    Silvana Jirka, Annemieke Aartsma-Rus, An update on RNA-targeting therapies for neuromuscular disorders, Current Opinion in Neurology, 2015, 28, 5, 515

    CrossRef

  14. 14
    Tri Le Bao, Rakesh N. Veedu, Sue Fletcher, Steve D. Wilton, Antisense oligonucleotide development for the treatment of muscular dystrophies, Expert Opinion on Orphan Drugs, 2015, 1

    CrossRef

  15. 15
    Melvin M. Evers, Lodewijk J.A. Toonen, Willeke M.C. van Roon-Mom, Antisense oligonucleotides in therapy for neurodegenerative disorders, Advanced Drug Delivery Reviews, 2015, 87, 90

    CrossRef

  16. 16
    F. Shabanpoor, G. McClorey, A. F. Saleh, P. Jarver, M. J. A. Wood, M. J. Gait, Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy, Nucleic Acids Research, 2015, 43, 1, 29

    CrossRef

  17. 17
    Valeria Ricotti, Francesco Muntoni, Thomas Voit, Challenges of clinical trial design for DMD, Neuromuscular Disorders, 2015, 25, 12, 932

    CrossRef

  18. 18
    Ngoc B Lu-Nguyen, Susan A Jarmin, Amer F Saleh, Linda Popplewell, Michael J Gait, George Dickson, Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice, Molecular Therapy, 2015, 23, 8, 1341

    CrossRef

  19. 19
    James Hemphill, Qingyang Liu, Rajendra Uprety, Subhas Samanta, Michael Tsang, Rudolph L. Juliano, Alexander Deiters, Conditional Control of Alternative Splicing through Light-Triggered Splice-Switching Oligonucleotides, Journal of the American Chemical Society, 2015, 137, 10, 3656

    CrossRef

  20. 20
    Rui Xu, Neha Singhal, Yelda Serinagaoglu, Kumaran Chandrasekharan, Mandar Joshi, John A. Bauer, Paulus M.L. Janssen, Paul T. Martin, Deletion of Galgt2 (B4Galnt2) Reduces Muscle Growth in Response to Acute Injury and Increases Muscle Inflammation and Pathology in Dystrophin-Deficient Mice, The American Journal of Pathology, 2015, 185, 10, 2668

    CrossRef

  21. 21
    Prisca Boisguérin, Sébastien Deshayes, Michael J. Gait, Liz O'Donovan, Caroline Godfrey, Corinne A. Betts, Matthew J.A. Wood, Bernard Lebleu, Delivery of therapeutic oligonucleotides with cell penetrating peptides, Advanced Drug Delivery Reviews, 2015, 87, 52

    CrossRef

  22. 22
    Eric Wickstrom, DNA and RNA derivatives to optimize distribution and delivery, Advanced Drug Delivery Reviews, 2015, 87, 25

    CrossRef

  23. 23
    Eppie M Yiu, Andrew J Kornberg, Duchenne muscular dystrophy, Journal of Paediatrics and Child Health, 2015, 51, 8
  24. 24
    Perry B. Shieh, Duchenne muscular dystrophy, Current Opinion in Neurology, 2015, 28, 5, 542

    CrossRef

  25. 25
    Camilla Brolin, Takehiko Shiraishi, Pernille Hojman, Thomas O Krag, Peter E Nielsen, Julie Gehl, Electroporation Enhanced Effect of Dystrophin Splice Switching PNA Oligomers in Normal and Dystrophic Muscle, Molecular Therapy—Nucleic Acids, 2015, 4, 12, e267

    CrossRef

  26. 26
    Maria Candida Vila, Margaret Benny Klimek, James S. Novak, Sree Rayavarapu, Kitipong Uaesoontrachoon, Jessica F. Boehler, Alyson A. Fiorillo, Marshall W. Hogarth, Aiping Zhang, Conner Shaughnessy, Heather Gordish-Dressman, Umar Burki, Volker Straub, Qi Long Lu, Terence A. Partridge, Kristy J. Brown, Yetrib Hathout, John van den Anker, Eric P. Hoffman, Kanneboyina Nagaraju, Elusive sources of variability of dystrophin rescue by exon skipping, Skeletal Muscle, 2015, 5, 1

    CrossRef

  27. 27
    Yoshiaki Masaki, Takeshi Inde, Tetsuya Nagata, Jun Tanihata, Takashi Kanamori, Kohji Seio, Shin'ichi Takeda, Mitsuo Sekine, Enhancement of exon skipping in mdx52 mice by 2′-O-methyl-2-thioribothymidine incorporation into phosphorothioate oligonucleotides, Med. Chem. Commun., 2015, 6, 4, 630

    CrossRef

  28. 28
    Paulo JC Lin, Ying K Tam, Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems, Future Medicinal Chemistry, 2015, 7, 13, 1751

    CrossRef

  29. 29
    Silvana M G Jirka, Christa L Tanganyika-de Winter, Joke W Boertje-van der Meulen, Maaike van Putten, Monika Hiller, Rick Vermue, Peter C de Visser, Annemieke Aartsma-Rus, Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy, Molecular Therapy—Nucleic Acids, 2015, 4, 12, e265

    CrossRef

  30. 30
    Ryszard Kole, Arthur M. Krieg, Exon skipping therapy for Duchenne muscular dystrophy, Advanced Drug Delivery Reviews, 2015, 87, 104

    CrossRef

  31. 31
    Aurélie Goyenvalle, Graziella Griffith, Arran Babbs, Samir El Andaloussi, Kariem Ezzat, Aurélie Avril, Branislav Dugovic, Rémi Chaussenot, Arnaud Ferry, Thomas Voit, Helge Amthor, Claudia Bühr, Stefan Schürch, Matthew J A Wood, Kay E Davies, Cyrille Vaillend, Christian Leumann, Luis Garcia, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nature Medicine, 2015,

    CrossRef

  32. 32
    Nicolas Wein, Lindsay Alfano, Kevin M. Flanigan, Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy, Pediatric Clinics of North America, 2015, 62, 3, 723

    CrossRef

  33. 33
    L. Peverelli, S. Testolin, L. Villa, A. D'Amico, S. Petrini, C. Favero, F. Magri, L. Morandi, M. Mora, T. Mongini, E. Bertini, M. Sciacco, G. P. Comi, M. Moggio, Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy, Neurology, 2015, 85, 21, 1886

    CrossRef

  34. 34
    Kristin N. Heller, Chrystal L. Montgomery, Kimberly M. Shontz, K. Reed Clark, Jerry R. Mendell, Louise R. Rodino-Klapac, Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice, Human Gene Therapy, 2015, 26, 10, 647

    CrossRef

  35. 35
    Luciano Merlini, Patrizia Sabatelli, Improving clinical trial design for Duchenne muscular dystrophy, BMC Neurology, 2015, 15, 1

    CrossRef

  36. 36
    Yuchen Nan, Zexu Ma, Harilakshmi Kannan, David A. Stein, Patrick I. Iversen, Xiang-Jin Meng, Yan-Jin Zhang, Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers, Antiviral Research, 2015, 120, 134

    CrossRef

  37. 37
    Masafumi Matsuo, Investigational treatments and therapeutic targets in Becker muscular dystrophy, Expert Opinion on Orphan Drugs, 2015, 3, 7, 821

    CrossRef

  38. 38
    Natassia M. Vieira, Ingegerd Elvers, Matthew S. Alexander, Yuri B. Moreira, Alal Eran, Juliana P. Gomes, Jamie L. Marshall, Elinor K. Karlsson, Sergio Verjovski-Almeida, Kerstin Lindblad-Toh, Louis M. Kunkel, Mayana Zatz, Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype, Cell, 2015, 163, 5, 1204

    CrossRef

  39. 39
    Yetrib Hathout, Edward Brody, Paula R. Clemens, Linda Cripe, Robert Kirk DeLisle, Pat Furlong, Heather Gordish-Dressman, Lauren Hache, Erik Henricson, Eric P. Hoffman, Yvonne Monique Kobayashi, Angela Lorts, Jean K. Mah, Craig McDonald, Bob Mehler, Sally Nelson, Malti Nikrad, Britta Singer, Fintan Steele, David Sterling, H. Lee Sweeney, Steve Williams, Larry Gold, Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy, Proceedings of the National Academy of Sciences, 2015, 112, 23, 7153

    CrossRef

  40. 40
    Yusuke Echigoya, Yoshitsugu Aoki, Bailey Miskew, Dharminder Panesar, Aleksander Touznik, Tetsuya Nagata, Jun Tanihata, Akinori Nakamura, Kanneboyina Nagaraju, Toshifumi Yokota, Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice, Molecular Therapy—Nucleic Acids, 2015, 4, 2, e225

    CrossRef

  41. 41
    Thomas C. Roberts, Henrik J. Johansson, Graham McClorey, Caroline Godfrey, K. Emelie M. Blomberg, Thibault Coursindel, Michael J. Gait, C.I. Edvard Smith, Janne Lehtiö, Samir EL Andaloussi, Matthew J.A. Wood, Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration, Human Molecular Genetics, 2015, 24, 23, 6756

    CrossRef

  42. 42
    Laurent Servais, Marie Montus, Caroline Le Guiner, Rabah Ben Yaou, Mélanie Annoussamy, Amélie Moraux, Jean-Yves Hogrel, Andreea M. Seferian, Karima Zehrouni, Anne-Gaëlle Le Moing, Teresa Gidaro, Catherine Vanhulle, Vincent Laugel, Nina Butoianu, Jean-Marie Cuisset, Pascal Sabouraud, Claude Cances, Andrea Klein, France Leturcq, Philippe Moullier, Thomas Voit, Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype, Journal of Neuromuscular Diseases, 2015, 2, 3, 269

    CrossRef

  43. 43
    Vivek K Sharma, Jonathan K Watts, Oligonucleotide therapeutics: chemistry, delivery and clinical progress, Future Medicinal Chemistry, 2015, 7, 16, 2221

    CrossRef

  44. 44
    Liz O'Donovan, Itaru Okamoto, Andrey A. Arzumanov, Donna L. Williams, Peter Deuss, Michael J. Gait, Parallel Synthesis of Cell-Penetrating Peptide Conjugates of PMO Toward Exon Skipping Enhancement in Duchenne Muscular Dystrophy, Nucleic Acid Therapeutics, 2015, 25, 1, 1

    CrossRef

  45. 45
    Xianjun Gao, Xiaoyong Shen, Xue Dong, Ning Ran, Gang Han, Limin Cao, Ben Gu, HaiFang Yin, Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice, Molecular Therapy—Nucleic Acids, 2015, 4, 10, e255

    CrossRef

  46. 46
    Richard S. Geary, Daniel Norris, Rosie Yu, C. Frank Bennett, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides, Advanced Drug Delivery Reviews, 2015, 87, 46

    CrossRef

  47. 47
    J. T. Selsby, J. W. Ross, D. Nonneman, K. Hollinger, Porcine Models of Muscular Dystrophy, ILAR Journal, 2015, 56, 1, 116

    CrossRef

  48. 48
    Anna Wojtuszkiewicz, Yehuda G Assaraf, Marielle JP Maas, Gertjan JL Kaspers, Gerrit Jansen, Jacqueline Cloos, Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance, Expert Opinion on Drug Metabolism & Toxicology, 2015, 11, 5, 673

    CrossRef

  49. 49
    Yongping Yue, Ibrahim M. Binalsheikh, Stacey B. Leach, Timothy L. Domeier, Dongsheng Duan, Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy, Expert Opinion on Orphan Drugs, 2015, 1

    CrossRef

  50. 50
    Kane Greer, Kayla Mizzi, Emily Rice, Lukas Kuster, Roberto A. Barrero, Matthew I. Bellgard, Bryan J. Lynch, Aileen Reghan Foley, Eoin O Rathallaigh, Steve D. Wilton, Sue Fletcher, Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient, Molecular Genetics & Genomic Medicine, 2015, 3, 4
  51. 51
    Jay J. Han, Gregorij Kurillo, Richard T. Abresch, Evan Bie, Alina Nicorici, Ruzena Bajcsy, Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect, Muscle & Nerve, 2015, 51, 2
  52. 52
    Monica Nizzardo, Chiara Simone, Sara Dametti, Sabrina Salani, Gianna Ulzi, Serena Pagliarani, Federica Rizzo, Emanuele Frattini, Franco Pagani, Nereo Bresolin, Giacomo Comi, Stefania Corti, Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches, Scientific Reports, 2015, 5, 11746

    CrossRef

  53. 53
    S.D. Wilton, R.N. Veedu, S. Fletcher, The emperor's new dystrophin: finding sense in the noise, Trends in Molecular Medicine, 2015, 21, 7, 417

    CrossRef

  54. 54
    Adeline Vulin, Nicolas Wein, Tabatha R. Simmons, Andrea M. Rutherford, Andrew R. Findlay, Jacqueline A. Yurkoski, Yuuki Kaminoh, Kevin M. Flanigan, The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development, Neuromuscular Disorders, 2015, 25, 11, 827

    CrossRef

  55. 55
    Simon Guiraud, Annemieke Aartsma-Rus, Natassia M. Vieira, Kay E. Davies, Gert-Jan B. van Ommen, Louis M. Kunkel, The Pathogenesis and Therapy of Muscular Dystrophies, Annual Review of Genomics and Human Genetics, 2015, 16, 1, 281

    CrossRef

  56. 56
    Aiping Zhang, Kitipong Uaesoontrachoon, Conner Shaughnessy, Jharna R. Das, Sree Rayavarapu, Kristy J. Brown, Patricio E. Ray, Kanneboyina Nagaraju, John N. van den Anker, Eric P. Hoffman, Yetrib Hathout, The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse, Toxicology Reports, 2015, 2, 838

    CrossRef

  57. 57
    Alyson A. Fiorillo, Christopher R. Heier, James S. Novak, Christopher B. Tully, Kristy J. Brown, Kitipong Uaesoontrachoon, Maria C. Vila, Peter P. Ngheim, Luca Bello, Joe N. Kornegay, Corrado Angelini, Terence A. Partridge, Kanneboyina Nagaraju, Eric P. Hoffman, TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy, Cell Reports, 2015, 12, 10, 1678

    CrossRef

  58. 58
    Mingxing Wang, Bo Wu, Jason D. Tucker, Peijuan Lu, Lauren E. Bollinger, Qilong Lu, Tween 85 grafted PEIs enhanced delivery of antisense 2′-O-methyl phosphorothioate oligonucleotides in vitro and in dystrophic mdx mice, J. Mater. Chem. B, 2015, 3, 26, 5330

    CrossRef

  59. 59
    Jay J. Han, Gregorij Kurillo, Richard T. Abresch, Evan De Bie, Alina Nicorici, Ruzena Bajcsy, Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect, Muscle & Nerve, 2015, 52, 3
  60. 60
    Jennifer Manning, Dervla O’Malley, What has the mdx mouse model of duchenne muscular dystrophy contributed to our understanding of this disease?, Journal of Muscle Research and Cell Motility, 2015, 36, 2, 155

    CrossRef

  61. 61
    Sara Benedetti, Giulio Cossu, Francesco Tedesco, Gene and Cell Therapy, 2015,

    CrossRef

  62. 62
    Jacqueline Montes, Petra Kaufmann, Neuromuscular Disorders of Infancy, Childhood, and Adolescence, 2015,

    CrossRef

  63. 63
    Eric P. Hoffman, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, 2015,

    CrossRef

  64. 64
    Louise R. Rodino-Klapac, Jerry R. Mendell, Neuromuscular Disorders of Infancy, Childhood, and Adolescence, 2015,

    CrossRef

  65. 65
    Peter Järver, Liz O'Donovan, Michael J. Gait, A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications, Nucleic Acid Therapeutics, 2014, 24, 1, 37

    CrossRef

  66. 66
    De-Ann M. Pillers, A new day for Duchenne's?: The time has come for newborn screening, Molecular Genetics and Metabolism, 2014, 113, 1-2, 11

    CrossRef

  67. You have full text access to this Open Access content67
    Janice A. Dominov, Özgün Uyan, Peter C. Sapp, Diane McKenna-Yasek, Babi R. R. Nallamilli, Madhuri Hegde, Robert H. Brown, A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides, Annals of Clinical and Translational Neurology, 2014, 1, 9
  68. 68
    Eric Hoffman, A rebirth for drisapersen in Duchenne muscular dystrophy?, The Lancet Neurology, 2014, 13, 10, 963

    CrossRef

  69. 69
    Belen Pérez, Lluisa Vilageliu, Daniel Grinberg, Lourdes R. Desviat, Antisense Mediated Splicing Modulation For Inherited Metabolic Diseases: Challenges for Delivery, Nucleic Acid Therapeutics, 2014, 24, 1, 48

    CrossRef

  70. 70
    Marcel Veltrop, Annemieke Aartsma-Rus, Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases, Experimental Cell Research, 2014, 325, 1, 50

    CrossRef

  71. 71
    C. Moorwood, E. R. Barton, Caspase-12 ablation preserves muscle function in the mdx mouse, Human Molecular Genetics, 2014, 23, 20, 5325

    CrossRef

  72. 72
    C. Aaron Larsen, Michael T. Howard, Conserved regions of the DMD 3′ UTR regulate translation and mRNA abundance in cultured myotubes, Neuromuscular Disorders, 2014, 24, 8, 693

    CrossRef

  73. 73
    Suzan M Hammond, Graham McClorey, Joel Z Nordin, Caroline Godfrey, Sofia Stenler, Kim A Lennox, CI Edvard Smith, Ashley M Jacobi, Miguel A Varela, Yi Lee, Mark A Behlke, Matthew J A Wood, Samir E L Andaloussi, Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides, Molecular Therapy—Nucleic Acids, 2014, 3, 11, e212

    CrossRef

  74. 74
    Terence Partridge, Could Exon Skipping Help Dystrophic Boys to Run, Hop, and Jump?, Molecular Therapy, 2014, 22, 11, 1884

    CrossRef

  75. 75
    Takenori Shimo, Keisuke Tachibana, Kiwamu Saito, Tokuyuki Yoshida, Erisa Tomita, Reiko Waki, Tsuyoshi Yamamoto, Takefumi Doi, Takao Inoue, Junji Kawakami, Satoshi Obika, Design and evaluation of locked nucleic acid-based splice-switching oligonucleotidesin vitro, Nucleic Acids Research, 2014, 42, 12, 8174

    CrossRef

  76. 76
    Petra Disterer, Adrianna Kryczka, Yuqi Liu, Yusef E. Badi, Jessie J. Wong, James S. Owen, Bernard Khoo, Development of Therapeutic Splice-Switching Oligonucleotides, Human Gene Therapy, 2014, 25, 7, 587

    CrossRef

  77. 77
    Y. Hathout, R. L. Marathi, S. Rayavarapu, A. Zhang, K. J. Brown, H. Seol, H. Gordish-Dressman, S. Cirak, L. Bello, K. Nagaraju, T. Partridge, E. P. Hoffman, S. Takeda, J. K. Mah, E. Henricson, C. McDonald, Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients, Human Molecular Genetics, 2014, 23, 24, 6458

    CrossRef

  78. 78
    Kevin M. Flanigan, Duchenne and Becker Muscular Dystrophies, Neurologic Clinics, 2014, 32, 3, 671

    CrossRef

  79. 79
    Steve D. Wilton, Sue Fletcher, Kevin M. Flanigan, Dystrophin as a therapeutic biomarker: Are we ignoring data from the past?, Neuromuscular Disorders, 2014, 24, 6, 463

    CrossRef

  80. 80
    Mingxing Wang, Bo Wu, Jay D. Tucker, Peijuan Lu, Caryn Cloer, Qi Long Lu, Evaluation of Tris[2-(Acryloyloxy)Ethyl]Isocyanurate Cross-Linked Polyethylenimine as Antisense Morpholino Oligomer Delivery Vehicle in Cell Culture and DystrophicmdxMice, Human Gene Therapy, 2014, 25, 5, 419

    CrossRef

  81. 81
    B Wu, C Cloer, P Lu, S Milazi, M Shaban, S N Shah, L Marston-Poe, H M Moulton, Q L Lu, Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice, Gene Therapy, 2014, 21, 9, 785

    CrossRef

  82. 82
    Ute Ayazpoor, Exon-Skipping bei Muskeldystrophie vom Typ Duchenne, DNP - Der Neurologe und Psychiater, 2014, 15, 5, 12

    CrossRef

  83. 83
    E. P. Hoffman, E. M. McNally, Exon-Skipping Therapy: A Roadblock, Detour, or Bump in the Road?, Science Translational Medicine, 2014, 6, 230, 230fs14

    CrossRef

  84. 84
    Rabi Tawil, Silvère M van der Maarel, Stephen J Tapscott, Facioscapulohumeral dystrophy: the path to consensus on pathophysiology, Skeletal Muscle, 2014, 4, 1, 12

    CrossRef

  85. 85
    Caroline Le Guiner, Marie Montus, Laurent Servais, Yan Cherel, Virginie Francois, Jean-Laurent Thibaud, Claire Wary, Béatrice Matot, Thibaut Larcher, Lydie Guigand, Maeva Dutilleul, Claire Domenger, Marine Allais, Maud Beuvin, Amélie Moraux, Johanne Le Duff, Marie Devaux, Nicolas Jaulin, Mickaël Guilbaud, Virginie Latournerie, Philippe Veron, Sylvie Boutin, Christian Leborgne, Diana Desgue, Jack-Yves Deschamps, Sophie Moullec, Yves Fromes, Adeline Vulin, Richard H Smith, Nicolas Laroudie, Frédéric Barnay-Toutain, Christel Rivière, Stéphanie Bucher, Thanh-Hoa Le, Nicolas Delaunay, Mehdi Gasmi, Robert M Kotin, Gisèle Bonne, Oumeya Adjali, Carole Masurier, Jean-Yves Hogrel, Pierre Carlier, Philippe Moullier, Thomas Voit, Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients, Molecular Therapy, 2014, 22, 11, 1923

    CrossRef

  86. 86
    Samiah Al-Zaidy, Louise Rodino-Klapac, Jerry R. Mendell, Gene Therapy for Muscular Dystrophy: Moving the Field Forward, Pediatric Neurology, 2014, 51, 5, 607

    CrossRef

  87. 87
    Thomas Gintjee, Alvin Magh, Carmen Bertoni, High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics, Biology, 2014, 3, 4, 752

    CrossRef

  88. 88
    Matthew S. Alexander, Juan Carlos Casar, Norio Motohashi, Natássia M. Vieira, Iris Eisenberg, Jamie L. Marshall, Molly J. Gasperini, Angela Lek, Jennifer A. Myers, Elicia A. Estrella, Peter B. Kang, Frederic Shapiro, Fedik Rahimov, Genri Kawahara, Jeffrey J. Widrick, Louis M. Kunkel, MicroRNA-486–dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy–associated symptoms, Journal of Clinical Investigation, 2014, 124, 6, 2651

    CrossRef

  89. 89
    Aleksander Touznik, Joshua JA Lee, Toshifumi Yokota, New developments in exon skipping and splice modulation therapies for neuromuscular diseases, Expert Opinion on Biological Therapy, 2014, 14, 6, 809

    CrossRef

  90. 90
    Satyakam Bhagavati, Questions about efficacy of exon-skipping therapy for duchenne muscular dystrophy, Annals of Neurology, 2014, 75, 2
  91. 91
    Matthew I. Bellgard, Mark W. Sleeman, Felix D. Guerrero, Sue Fletcher, Gareth Baynam, Jack Goldblatt, Yaffa Rubinstein, Callum Bell, Stephen Groft, Roberto Barrero, Alan H. Bittles, Stephen D. Wilton, Christopher E. Mason, Tarun Weeramanthri, Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes, Health Policy and Technology, 2014, 3, 4, 325

    CrossRef

  92. 92
    Jerry R. Mendell, Ed M. Kaye, Reply, Annals of Neurology, 2014, 75, 2
  93. 93
    Thomas Voit, Haluk Topaloglu, Volker Straub, Francesco Muntoni, Nicolas Deconinck, Giles Campion, Sjef J De Kimpe, Michelle Eagle, Michela Guglieri, Steve Hood, Lia Liefaard, Afrodite Lourbakos, Allison Morgan, Joanna Nakielny, Naashika Quarcoo, Valeria Ricotti, Katie Rolfe, Laurent Servais, Claire Wardell, Rosamund Wilson, Padraig Wright, John E Kraus, Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study, The Lancet Neurology, 2014, 13, 10, 987

    CrossRef

  94. 94
    Kane L Greer, Hanns Lochmüller, Kevin Flanigan, Susan Fletcher, Steve D Wilton, Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene, Molecular Therapy—Nucleic Acids, 2014, 3, 3, e155

    CrossRef

  95. You have free access to this content95
    Simon A Smith, Tim French, Simon J Hollingsworth, The impact of germline mutations on targeted therapy, The Journal of Pathology, 2014, 232, 2
  96. 96
    Jane T. Seto, Niclas E. Bengtsson, Jeffrey S. Chamberlain, Therapy of Genetic Disorders: Novel Therapies for Duchenne Muscular Dystrophy, Current Pediatrics Reports, 2014, 2, 2, 102

    CrossRef

  97. 97
    Annemieke Aartsma-Rus, Alessandra Ferlini, Nathalie Goemans, Anna M.G. Pasmooij, Dominic J. Wells, Katerine Bushby, Elizabeth Vroom, Pavel Balabanov, Translational and Regulatory Challenges for Exon Skipping Therapies, Human Gene Therapy, 2014, 25, 10, 885

    CrossRef

  98. 98
    Emma Tabe Eko Niba, Van Khanh Tran, Le Anh Tuan-Pham, Dung Chi Vu, Ngoc Khanh Nguyen, Van Thanh Ta, Thinh Huy Tran, Tomoko Lee, Yasuhiro Takeshima, Masafumi Matsuo, Validation of ambiguous MLPA results by targeted next-generation sequencing discloses a nonsense mutation in the DMD gene, Clinica Chimica Acta, 2014, 436, 155

    CrossRef

  99. 99
    Qi-long Lu, Sebahattin Cirak, Terence Partridge, What Can We Learn From Clinical Trials of Exon Skipping for DMD?, Molecular Therapy—Nucleic Acids, 2014, 3, 3, e152

    CrossRef

  100. 100
    Umasuthan Srirangalingam, Bernard Khoo, Splicing Modulation as Therapy for Human Genetic Disease, eLS,